全文获取类型
收费全文 | 20496篇 |
免费 | 1477篇 |
国内免费 | 687篇 |
专业分类
耳鼻咽喉 | 134篇 |
儿科学 | 369篇 |
妇产科学 | 225篇 |
基础医学 | 1033篇 |
口腔科学 | 449篇 |
临床医学 | 1437篇 |
内科学 | 1843篇 |
皮肤病学 | 193篇 |
神经病学 | 583篇 |
特种医学 | 632篇 |
外国民族医学 | 7篇 |
外科学 | 2435篇 |
综合类 | 2097篇 |
一般理论 | 1篇 |
预防医学 | 1846篇 |
眼科学 | 293篇 |
药学 | 5710篇 |
12篇 | |
中国医学 | 1530篇 |
肿瘤学 | 1831篇 |
出版年
2024年 | 47篇 |
2023年 | 352篇 |
2022年 | 659篇 |
2021年 | 827篇 |
2020年 | 806篇 |
2019年 | 792篇 |
2018年 | 770篇 |
2017年 | 817篇 |
2016年 | 833篇 |
2015年 | 735篇 |
2014年 | 1245篇 |
2013年 | 1930篇 |
2012年 | 1112篇 |
2011年 | 1250篇 |
2010年 | 958篇 |
2009年 | 938篇 |
2008年 | 907篇 |
2007年 | 941篇 |
2006年 | 816篇 |
2005年 | 688篇 |
2004年 | 608篇 |
2003年 | 511篇 |
2002年 | 423篇 |
2001年 | 382篇 |
2000年 | 303篇 |
1999年 | 308篇 |
1998年 | 256篇 |
1997年 | 259篇 |
1996年 | 213篇 |
1995年 | 207篇 |
1994年 | 191篇 |
1993年 | 178篇 |
1992年 | 136篇 |
1991年 | 111篇 |
1990年 | 126篇 |
1989年 | 105篇 |
1988年 | 125篇 |
1987年 | 83篇 |
1986年 | 57篇 |
1985年 | 114篇 |
1984年 | 97篇 |
1983年 | 84篇 |
1982年 | 87篇 |
1981年 | 43篇 |
1980年 | 50篇 |
1979年 | 35篇 |
1978年 | 32篇 |
1977年 | 25篇 |
1976年 | 33篇 |
1975年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献5.
《Clinical genitourinary cancer》2022,20(5):442-451
IntroductionSelective internal radiation therapy (SIRT) is a potential treatment of primary renal cell carcinoma (RCC) deemed unsuitable for conventional therapy. RESIRT is the first-in-human study to evaluate safety and feasibility of SIRT for primary RCC.Patients and MethodsPatients with RCC, unsuitable for, or who declined conventional therapy, were eligible. A single transfemoral micro-catheter administration of yttrium-90 (Y-90) resin microspheres (SIR-Spheres) was delivered super selectively via the renal artery to the tumour at intended radiation doses of 75, 100, 150, 200, 300 Gy and a final cohort with a procedural endpoint of “imminent stasis,” in a dose-escalation design. Post-SIRT follow-up was 12 months. Study endpoints included safety and toxicity 30-days and 12-months post-SIRT and tumour response (RECIST v1.1).ResultsIn total, 21 patients were enrolled, mean (SD) age was 75 (9.3) years, WHO performance status was 0 in 81%, 12 (57%) had stage 3 chronic kidney disease, and 7 (33%) had prior contralateral nephrectomy. Overall, 71% of patients completed 12 months of follow-up. Intended doses were delivered without any dose-limiting toxicity. Seventeen out of 21 (81%) patients experienced an adverse event (AE) from any cause within 30 days post-SIRT; all SIRT-related AEs were grade 1 to 2. Best overall tumour responses were partial response 1/21 (4.8%), stable disease 19/21 (90.5%) and progressive disease 1/21 (4.8%).ConclusionThis study demonstrated good tolerability of SIRT at all dose levels including “imminent stasis” in treating primary tumours in RCC patients otherwise unsuitable for conventional therapy. SIRT with Y-90 resin microspheres may be a feasible treatment option for RCC. 相似文献
6.
《Seminars in Arthroplasty》2022,32(4):681-687
BackgroundThe objective of this study was to compare complication rates between patients undergoing reverse shoulder arthroplasty (RSA) after a prior open reduction and internal fixation (ORIF) for proximal humerus fracture (PHF) to those undergoing RSA as a primary treatment for PHFs, glenohumeral osteoarthritis, or rotator cuff tear arthropathy (CTA).MethodsPatients who underwent RSA between 2015 and 2020 were identified in the Mariner database. Patients were separated into 3 mutually exclusive groups: (1) RSA for osteoarthritis, rotator cuff tear, or CTA (Control-RSA); (2) RSA as a primary treatment for PHF (PHF-RSA); and (3) RSA for patients with prior ORIF of PHFs (ORIF-RSA). Ninety-day medical and 2-year postoperative surgical complications were identified. In addition, patients in the PHF-RSA group were subdivided into those undergoing RSA for PHF within 3 months of the fracture (acute) vs. those treated greater than 3 months from diagnosis (delayed). Multivariate regression was performed to control for differences in comorbidities and demographics.ResultsA total of 30,824 patients underwent primary RSA for arthritis or CTA, 5389 patients underwent RSA as a primary treatment for a PHF, and 361 patients underwent RSA after ORIF of a PHF. ORIF before RSA was associated with an increased risk of overall revision (odds ratio [OR] 2.45, P = .002), infection (OR 2.40, P < .001), instability (OR 2.43, P < .001), fracture (OR 3.24, P = .001), minor medical complications (OR 1.59, P = .008), and readmission (OR 2.55, P = .001) compared with the Control-RSA cohort. RSA as a primary treatment for PHF was associated with an increased risk of 2-year revision (OR 1.60, P < .001), infection (OR 1.51, P < .001), instability (OR 2.84, P < .001), and fracture (OR 2.54, P < .001) in addition to major medical complications (OR 2.02, P < .001), minor medical complications (OR 1.92, P < .001), 90-day emergency department visits (OR 1.26, P < .001) and 90-day readmission (OR 2.03, P < .001) compared with the Control-RSA cohort. The ORIF-RSA group had an increased risk of periprosthetic infection (OR 1.94, P = .002) when compared with the PHF-RSA cohort. There were no differences in medical or surgical complications in the RSA-PHF cohort between patients treated in an acute or delayed fashion.ConclusionRSA following ORIF of a PHF is associated with increased complications compared with patients undergoing RSA for nonfracture indications. Prior ORIF of a PHF is also an independent risk factor for postoperative infection after RSA compared with patients who undergo RSA as a primary operation for fracture. The timing of RSA as a primary operation for PHF does not appear to impact the rates of postoperative medical and surgical complications. 相似文献
7.
8.
9.
Canada continues to experience an escalating opioid overdose crisis that has claimed more than 8000 lives in the country since 2016. The presence of the synthetic opioid fentanyl and its analogues is a central contributor to the increases in preventable opioid-related deaths. However, a number of converging social-structural factors (e.g., the continued criminalisation of drug use, political changes) and political barriers are also complicating and contributing to the current crisis. We briefly outline four harm reduction interventions (i.e., injectable opioid agonist treatment, naloxone distribution programs, overdose prevention sites, and drug checking services) as emerging and rapidly expanding responses to this crisis in Canada. These examples of innovation and expansion are encouraging but also occurring at the same time that the opioid overdose crisis shows few signs of abating. To truly address the crisis, Canada needs political environments at all government levels that are responsive and foster harm reduction innovation and drug policy experimentation. 相似文献
10.